Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxdilimab in moderate to severe Alopecia Areata
NCT05368103Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of daxdilimab in alopecia areata, sponsored by Amgen. Primary endpoint: Percent Change From Baseline in Severity of Alopecia Tool (SALT) at 24 weeks. Started Apr 2022; status: completed.
02
Drugs
daxdilimab
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05368103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05368103.